DexCom, Inc. (DXCM)
- Previous Close
130.71 - Open
131.26 - Bid 131.44 x 300
- Ask 131.72 x 300
- Day's Range
129.74 - 132.36 - 52 Week Range
74.75 - 142.00 - Volume
2,110,182 - Avg. Volume
3,052,422 - Market Cap (intraday)
50.703B - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
101.17 - EPS (TTM)
1.30 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
151.32
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
www.dexcom.comRecent News: DXCM
Performance Overview: DXCM
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXCM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXCM
Valuation Measures
Market Cap
50.70B
Enterprise Value
50.57B
Trailing P/E
101.16
Forward P/E
74.63
PEG Ratio (5yr expected)
2.44
Price/Sales (ttm)
15.45
Price/Book (mrq)
24.51
Enterprise Value/Revenue
13.96
Enterprise Value/EBITDA
55.16
Financial Highlights
Profitability and Income Statement
Profit Margin
14.95%
Return on Assets (ttm)
6.41%
Return on Equity (ttm)
25.78%
Revenue (ttm)
3.62B
Net Income Avi to Common (ttm)
541.5M
Diluted EPS (ttm)
1.30
Balance Sheet and Cash Flow
Total Cash (mrq)
2.72B
Total Debt/Equity (mrq)
125.40%
Levered Free Cash Flow (ttm)
477.08M
Research Analysis: DXCM
Company Insights: DXCM
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: DXCM
DXCM: Lowering target price to $143.00
DEXCOM INC has an Investment Rating of HOLD; a target price of $143.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetTRUP: Lowering target price to $18.00
TRUPANION INC has an Investment Rating of SELL; a target price of $18.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetDXCM: Raising target price to $147.00
DEXCOM INC has an Investment Rating of HOLD; a target price of $147.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetTRUP: Lowering target price to $23.00
TRUPANION INC has an Investment Rating of SELL; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target